Abstract: The present disclosure relates to a liquid-cooling radiating pipe and a vacuum interrupter with a built-in liquid-cooling radiating pipe, belonging to the field of vacuum circuit breakers. Based on an original structure of an vacuum interrupter, a liquid-cooling radiating pipe of a Tesla valve structure is arranged in a conductive rod of the vacuum interrupter with the built-in liquid-cooling radiating pipe, and liquid metal is used as a circulating coolant in the liquid-cooling radiating pipe, and by using the self-circulating flow of the liquid metal in the pipeline, the capacity of the conductive rod to dissipate heat to the outside is significantly increased, and the problem of excessive internal temperature rise of a vacuum circuit breaker is effectively solved.

Abstract: A method for forming an ultrafine-pitch all-copper interconnect structure is provided. Nano-copper particles are mixed with a solvent, a dispersant and a viscosity modifier to prepare a nano-copper paste. A chip with a preset number of copper pillars having a preset diameter and a substrate are selected, cleaned and pretreated. The chip is sucked and flipped by a bonding machine to make the copper pillars face outward. The chip is sucked through a suction nozzle of the bonding machine and dipped in the nano-copper paste. A protective gas is fed, and the copper pillars are aligned with copper pads on the substrate through an optical system of the bonding machine, bonded with the substrate at a preset pressure and temperature under ultrasonication, and cooled at room temperature to obtain the interconnect structure. An ultrafine-pitch all-copper interconnect structure fabricated by the method is also provided.

Abstract: Provided are a cell strain for producing a biosimilar drug of Ustekinumab and a production method therefor. Specifically, provided is a Chinese hamster ovary cell S cell strain. The cell strain expresses a full human monoclonal antibody directed against the P40 subunit shared by human IL-12 and human IL-23. The fully human monoclonal antibody directed against the P40 subunit shared by human IL-12 and human IL-23 is a biosimilar drug of Ustekinumab, which not only exhibits high consistency with Ustekinumab in pre-clinical research, but also passes pharmacokinetic bioequivalence and safety similarity evaluation in clinical research. The biosimilar drug of Ustekinumab is the first one that has entered clinical trials in China, is the only one that has completed the I stage clinical trial, and is also one of the biosimilar drugs of Ustekinumab, which has the fastest progress in new drug application in the world.

Abstract: The present disclosure provides a microphone, comprising a shell structure, a vibration pickup assembly, a vibration pickup assembly, wherein the vibration pickup assembly is accommodated in the shell structure and generates vibration in response to an external sound signal transmitted to the shell structure, and at least two acoustoelectric conversion elements configured to respectively receive the vibration of the vibration pickup assembly to generate an electrical signal, wherein the at least two acoustoelectric conversion elements have different frequency responses to the vibration of the vibration pickup assembly.

Abstract: A heat exchanger includes a fin set formed by a plurality of fins stacked together and a refrigerant pipe set passing through the fin set. The fin set includes a connection member, and a first fin member and a second fin member connected to each other via the connection member. An included angle between the first fin member and the second fin member is larger than zero. The first fin member and the second fin member are arranged at two sides, respectively, of a notch of the fin set. The notch is located at an air input side and/or an air output side of the connection member.

Abstract: Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.

Abstract: Certain aspects and features relate to a system that includes a drilling tool, a processor, and a non-transitory memory device that includes instructions that are executable by the processor to cause the processor to perform operations. The operations include receiving input data that corresponds to characteristics of at least one of drilling fluid, a drillstring, or a wellbore. The operations also include calculating at least one dynamic sideforce and at least one dynamic, hydraulic force based at least in part on the input data. The operations also include determining an equilibrium solution for an output value using the at least one dynamic sideforce and at least one dynamic, hydraulic force. The operations also include applying the output value to the drilling tool for controlling operation of the drilling tool.

Abstract: Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.

Abstract: Certain aspects and features relate to a system that includes a drilling tool, a processor, and a non-transitory memory device that includes instructions that are executable by the processor to cause the processor to perform operations. The operations include receiving input data that corresponds to characteristics of at least one of drilling fluid, a drillstring, or a wellbore. The operations also include calculating at least one dynamic sideforce and at least one dynamic, hydraulic force based at least in part on the input data. The operations also include determining an equilibrium solution for an output value using the at least one dynamic sideforce and at least one dynamic, hydraulic force. The operations also include applying the output value to the drilling tool for controlling operation of the drilling tool.

Abstract: Certain aspects and features relate to a system that selects an output value for controlling a drilling tool using dynamic force analysis coupled to fluid effects as part of a model that estimates projected torque and drag. A drilling model according to aspects and features of the present disclosure takes into account pipe axial elasticity as it relates to dynamic, time-based, force analysis and couples this relationship with drilling fluid effects over time. In some examples, a system calculates at least one dynamic sideforce and at least one dynamic, hydraulic force for each interval of time. An equilibrium solution for an output value using the dynamic sideforce and dynamic, hydraulic force for each time interval can be applied to the drilling tool for each time interval during drilling operations.

Abstract: Certain aspects and features relate to a system that selects an output value for controlling a drilling tool using dynamic force analysis coupled to fluid effects as part of a model that estimates projected torque and drag. A drilling model according to aspects and features of the present disclosure takes into account pipe axial elasticity as it relates to dynamic, time-based, force analysis and couples this relationship with drilling fluid effects over time. In some examples, a system calculates at least one dynamic sideforce and at least one dynamic, hydraulic force for each interval of time. An equilibrium solution for an output value using the dynamic sideforce and dynamic, hydraulic force for each time interval can be applied to the drilling tool for each time interval during drilling operations.

Abstract: Provided herein are spirolactone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The spirolactone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/or ACC2 activities, for example, non-alcoholic steatohepatitis (NASH), acne, obesity, diabetes, and cancer. Also provided herein are pharmaceutical compositions comprising the spirolactone compound of Formula I, or pharmaceutically acceptable salt thereof.

Abstract: The present disclosure discloses a semiconductor apparatus and method of manufacturing. The apparatus includes: a circuit device and a heat sink fin that are disposed in a laminated manner, and a thermal interface material layer located between the circuit device and the heat sink fin. A packaging layer is disposed around a side wall of the circuit device. A first surface of the thermal interface material layer is thermally coupled to the circuit device and the packaging layer, and a second surface is thermally coupled to the heat sink fin. In the foregoing solution, the packaging layer and the circuit device are both thermally coupled to the thermal interface material layer, a contact area between the circuit device and the thermal interface material layer is increased.

Abstract: A large mode field active optical fiber and manufacture method thereof is provided. The large mode field active optical fiber is formed by drawing a fiber core (1), a quartz glass internal cladding (2), a quartz glass outer cladding (3), and a coating (4). The quartz glass internal cladding (2), the quartz glass outer cladding (3), and the coating (4) are sequentially coated on the outer surface of the fiber core (1). The fiber core (1) is formed by depositing, melting, and shrinking the tetrachlorosilane doped with rare earth ions in a quartz glass tube. The refractive index of the fiber core (1) is a graded refractive index, and the section parameter a thereof is 1???3. The appearance of the quartz glass inner cladding (2) is regular multi-prism shaped.

Abstract: A large mode field active optical fiber and manufacture method thereof is provided. The large mode field active optical fiber is formed by drawing a fiber core (1), a quartz glass internal cladding (2), a quartz glass outer cladding (3), and a coating (4). The quartz glass internal cladding (2), the quartz glass outer cladding (3), and the coating (4) are sequentially coated on the outer surface of the fiber core (1). The fiber core (1) is formed by depositing, melting, and shrinking the tetrachlorosilane doped with rare earth ions in a quartz glass tube. The refractive index of the fiber core (1) is a graded refractive index, and the section parameter a thereof is 1???3. The appearance of the quartz glass inner cladding (2) is regular multi-prism shaped.